

Samir Al Bashir, MD

Professor of Pathology & Laboratory Medicine | Consultant Histopathologist & Cytopathologist

Date of Birth: 10th October 1979
Place of Birth: Al Ramtha, Jordan
Nationality: Jordanian
Marital Status: Married

Email: smalbashir9@just.edu.jo
Telephone (Office): +962-2-7200600 Ext. 41336
Telephone (Mobile): +962 796804448
Google Scholar: [bit.ly/SamirAlBashir](https://scholar.google.com/citations?user=bit.ly/SamirAlBashir)

PROFESSIONAL PROFILE

Dedicated and accomplished Consultant Histopathologist and Professor with extensive expertise in Histopathology, Cytopathology, Uropathology, and Gastrointestinal Pathology. Driven by a steadfast commitment to precision diagnosis, multidisciplinary clinical collaboration, and institutional leadership. Proven track record in strategic university administration as Vice Dean, managing academic curricula, international relations, and research infrastructure. Actively contributes to advancing medical education and national medical standards as a member of the Scientific Board Exam Committee for Pathology within the Jordan Medical Council.

QUALIFICATIONS & CERTIFICATIONS

- **2013** — Canadian Fellowship in Cytopathology, University of Calgary, Alberta, Canada
- **2012** — Canadian Fellowship in Genitourinary (Uropathology) Pathology, University of Calgary, Canada
- **2012** — Canadian Fellowship in Gastrointestinal Pathology, University of Calgary, Alberta, Canada
- **2010** — Jordanian Board in Histopathology, Jordan Medical Council, Amman, Jordan
- **2010** — Higher Specialization Academic Degree in Pathology, Jordan University of Science and Technology, Irbid, Jordan
- **2004** — Doctor of Medicine (MD), State Medical and Pharmaceutical University 'Nicolae Testemitanu'

ADMINISTRATIVE POSTS & EXECUTIVE EXPERIENCE

Sep 2025 - Present — **Director**, Center for Sustainable Development Studies and Technology (CSDST), *Jordan University of Science and Technology*.

Sep 2024 - Present — **Director**, International Relations Office, *Jordan University of Science and Technology*.

Sep 2019 - Present — **Vice Dean**, Faculty of Medicine, *Jordan University of Science and Technology*.

- Serves as a pivotal leader shaping strategic direction, academic affairs, and administrative operations.
- Oversees curriculum development, accreditation processes, and faculty recruitment/retention to foster innovation and excellence.

Sep 2019 - Present — **Member of the Scientific Board Exam Committee for Pathology**, *Jordan Medical Council*.

- Collaborates to design, review, and refine examination materials and methodologies ensuring alignment with current medical advancements.

Sep 2018 - Sep 2019 — **Head**, Department of Pathology and Microbiology, *Jordan University of Science and Technology*.

- Directed academic, research, and day-to-day administrative operations; managed departmental budgeting, resource allocation, and personnel development.

Sep 2016 - Sep 2019 — **Assistant Dean for International Affairs**, Faculty of Medicine, *Jordan University of Science and Technology*.

- Spearheaded global initiatives, forged partnerships with overseas institutions, and facilitated international student/faculty exchanges.
-

ACADEMIC & CLINICAL APPOINTMENTS

- **Aug 2024 - Present** — **Full Professor in Pathology**, School of Medicine, *Jordan University of Science & Technology (JUST)* & *King Abdullah University Hospital (KAUH)*, Irbid, Jordan.
 - **Aug 2019 - Aug 2024** — **Associate Professor & Consultant Pathologist**, Department of Pathology & Laboratory Medicine, *JUST* & *KAUH*, Irbid, Jordan.
 - **Aug 2013 - Jul 2019** — **Assistant Professor & Consultant Pathologist**, Department of Pathology & Laboratory Medicine, *JUST* & *KAUH*, Irbid, Jordan.
 - **July 2012 - June 2013** — **Cytopathology Fellow**, Department of Pathology and Laboratory Medicine, *University of Calgary*, Alberta, Canada.
 - **Jan 2012 - June 2012** — **Genitourinary Pathology Fellow**, Department of Pathology and Laboratory Medicine, *University of Calgary*, Alberta, Canada.
 - **July 2011 - Dec 2011** — **Gastrointestinal Pathology Fellow**, Department of Pathology and Laboratory Medicine, *University of Calgary*, Alberta, Canada.
 - **Sep 2010 - June 2011** — **Teacher Assistant in Pathology**, *Jordan University of Science and Technology*, Irbid, Jordan.
 - **Oct 2009 - Feb 2010** — **Visiting Scholar / Elective Training**, Department of Pathology, *University of Michigan*, Ann Arbor, Michigan, USA.
 - **July 2006 - June 2010** — **Histopathology Resident**, *King Abdullah University Hospital (KAUH)*, Irbid, Jordan.
 - **April 2006 - June 2006** — **Locum Resident in General Surgery**, *King Abdullah University Hospital (KAUH)*, Irbid, Jordan.
 - **July 2005 - Mar 2006** — **General Practitioner**, *Irbid Specialty Hospital*, Irbid, Jordan.
 - **July 2004 - July 2005** — **Medical Intern**, *King Abdullah University Hospital (KAUH)*, Irbid, Jordan.
-

CLINICAL & DIAGNOSTIC EXPERIENCE

King Abdullah University Hospital (JUST, Jordan): Extensive diagnostic experience handling over 12,000 surgical pathology specimens and 3,000 to 4,000 cytology specimens annually. Expert proficiency in fine-needle aspiration (FNA) techniques, and intermediate intraoperative frozen section evaluations (~200 cases per year). Mentored junior residents and directed multidisciplinary tumor boards.

University of Calgary Fellowship Practice (Canada): Acquired detailed expertise across specialized diagnostic tracks including Gastrointestinal & Liver pathology (biopsies, complex resections, neoplastic and non-neoplastic diseases), Genitourinary pathology (case workups, uropathology sign-outs, presenting at local Genitourinary Tumor Boards), and Gynecological/Non-Gynecological Cytopathology including weekly FNA clinical practices.

EXTERNALLY FUNDED & COLLABORATIVE RESEARCH

- **Characterization of Novel Molecular Markers of Prostate Cancer in Middle Eastern Population**
Principal Investigator | Grant: 85,640 JD | Funded by The Scientific Research Support Fund (SRSF) (MPH/2/17/2015).
 - **The role of glutaminase expression in Jordanian breast cancer patients towards development and pharmacological characterization of a novel metformin/glutaminase inhibitor (CB-839) nanoparticle formulation**
Principal Investigator | Grant: 60,000 JD | Funded by The Scientific Research Support Fund (SRSF).
 - **Cyp27A1: A Biomarker and a Tool of Detection for Aggressive Prostate Cancer**
Co-Investigator | Grant: 30,000 JD | Funded by Deanship of Research, Jordan University of Science and Technology.
 - **The Incidence of Human Papilloma Virus in Laryngeal Carcinoma patients in North Jordan**
Co-Investigator | Grant: 8,900 JD | Funded by Deanship of Research, Jordan University of Science and Technology.
-

POSTGRADUATE ACADEMIC SUPERVISION (M.SC. COMMITTEES)

- **Aya Ahmad Smairat (JUST, 2018):** *Relationship between PTEN Mutations and Resistance to Androgen-Deprivation Therapy in Prostate Cancer in Jordan.*
 - **Manar M. Abu Al-Rub (Yarmouk University, 2020):** *Screening for CHK1 and CHK2 Mutations in Prostatic Carcinoma among Jordanians.*
 - **Basma Barham Al Zaareer (Yarmouk University, 2020):** *Screening of Sequence Variations in SPOP and IDH genes Associated with The Development of Prostate Cancer in Jordan.*
 - **Worood Rasmi Bani Baker (Yarmouk University, 2023):** *The Effect of Fentanyl Chronic Administration on Brain Tissues in Mice.*
 - **Sewar Raed Obeidat (Yarmouk University, 2023):** *The Association Between Male Infertility (asthenozoospermia) and the Mitochondrial Gene NADH-Ubiquinone Oxidoreductase Chain 4L(nd4l) Mutations in a Jordanian population.*
 - **Malak Alashqar (Yarmouk University, 2023):** *Relationship between IL1 Gene Polymorphisms and Periodontitis.*
 - **Said Feras Khaled Mayyas (Yarmouk University, 2024):** *Scanning Mitochondrially Encoded NADH Dehydrogenase Subunit 3 Gene (ND3) Variants in Asthenozoospermic Men in Jordan.*
-

PEER-REVIEWED PUBLICATIONS

1. **Rahallah, N., Al-Alami, Z., Alorjani, M. S., Al-Smadi, A., Obeidat, S., Ootom, R., Al Bashir, S., & Al Zoubi, M. S. (2026).** AKT2 Exon 3 Variants and Their Prevalence in Prostate Cancer. *Annals of Medical and Laboratory Sciences*.
2. **Alorjani, M. S., Al Bashir, S., Al-Zaareer, B., Alkhatib, S., Al-Zoubi, R. M., Al-Trad, B., ... & Al-Zoubi, M. S. (2025).** Prevalence of SPOP and IDH Gene Mutations in Prostate Cancer in a Jordanian Population. *Biochemical Genetics*, 63(6), 5258-5272.
3. **Basheer, H. A., Alkilani, A. Z., Al Bashir, S., Alhusban, M. A., Elsalem, L., & AlOmari, S. B. (2025).** Clinicopathological analysis of GLUT-1, GLS1, and GLS2 expression in breast cancer patients. *Tumor Biomarkers & Oncology Reports*.
4. **Al Bashir, S., Alorjani, M. S., Kheirallah, K., Al Hamad, M., Haddad, H. K., Al-Dwairy, A., Bani-Fawwaz, B. A., Aldaoud, N., Halalsheh, O., Amawi, S., & Matalaka, I. I. (2024).** PTEN, ERG, SPINK1, and TFF3 Status and Relationship in a Prostate Cancer Cohort from Jordanian Arab Population. *Medicina (Lithuania)*, 60(1), 134.
5. **Obeidat, M., Algargaz, W., Barukba, M., Bodoor, K., Mohamad, I., Barakat, F., & Al Bashir, S. (2024).** Clinical and molecular characteristics of Jordanian oropharyngeal cancer patients according to P16 expression: a retrospective study and a report of a novel biomarker. **Medical Molecular Morphology**, 57(2), 112-120.
6. **Al Bashir, S., AlBarakat, M. M., Alabedhalhim, K. K., Al-Khalaileh, Ali., Al-assaf, Amer., Saleh, Othman., Ayyad, A. W., & Alzoubi, K. H. (2024).** Knowledge of Cancer Symptoms and Risk Factors: A Cross-Sectional Study from a Developing Country. *Medicine*, 103(14), e37612.
7. **Al Bashir, S., Alorjani, M. S., Haddad, H. K., Matalaka, M. I., Obeidat, N., Matalaka, I. I., & Sobrinho-Simões, M. (2023).** Mature cystic teratoma of the ovary with malignant transformation of tall cell subtype of papillary thyroid carcinoma. *Virchows Archiv*, 483, 231-237.
8. **Alzoubi, A., Al Bashir, S., Smairat, A., Alrawashdeh, A., Haddad, H., & Kheirallah, K. (2023).** PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer: a study from Jordan. *Journal of Medicine and Life*, 16(4), 540-547.
9. **Alorjani, M., Aburub, M., Al-Trad, B., Al Hamad, M., AbuAlarja, M., Al Bashir, S., Al-Batayneh, K., & Zoubi, M. A. (2023).** The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study. *Medical Archives*, 77(1), 32-37.
10. **Melhem, A. B., Seif, A. M., Omar, O. H., Al Bashir, S., & Samrah, S. M. (2023).** COVID-19 and severe pulmonary alveolar proteinosis (PAP): A case report. *Heliyon*, 9(8), e18340.
11. **Al Bashir, S., Al-Azzam, N., Elsalem, L., Al Smerat, A., Haddad, H. K., Alsulaiman, J., Kheirallah, K. A., & Alzoubi, K. H. (2023).** Medical, Dental, and Nursing Students' Experience with Virtual Practical Sessions: A Cross-Sectional Study in a Developing Country. *Advances in Medical Education and Practice*, 14, 1065-1076.

12. **Elsalem, L., Alfaqih, M. A., Al Bashir, S., Halalsheh, O., Basheer, H. A., Mhedat, K., Khader, Y., & Pors, K. (2022).** Genetic variation in the ADIPOQ gene and serum adiponectin increase the risk of bladder cancer. *Journal of Applied Biomedicine*, 20(3), 114-122.
13. **Al Omari, A., Qarqaz, W., Alrhman, R. A., Al-Ashqar, R., Al Bashir, S., & Alorjani, M. (2022).** Nodular Fasciitis and Myxolipoma of the Larynx: A rare case report with brief literature review. *Sultan Qaboos University Medical Journal*, 22(4), 562-566.
14. **Fares, M., Ayoub, N. M., Marji, R., Al Bashir, S. M., & Al-Shari, O. M. (2022).** The impact of tumor-infiltrating lymphocytes on tumor features and pathological characteristics in breast cancer patients: The role of cytotoxic T lymphocytes and regulatory T cells. *European Review for Medical and Pharmacological Sciences*, 26(11), 3951-3963.
15. **Abdulrazeq, F., Kheirallah, K. A., Al-Mistarehi, A. H., Al Bashir, S., Alqudah, M. A., Alzoubi, A., Alsulaiman, J., Al Zoubi, M. S., & Al-Maamari, A. (2022).** Effectiveness of interactive teaching intervention on medical students' knowledge and attitudes toward stem cells, their therapeutic uses, and potential research applications. *PeerJ*, 10, e13142.
16. **Alorjani, M., Matalaka, I., Abu Baker, S., Al-Khatib, S., Al Bashir, S., & Al-Qudah, M. (2021).** Cellular pathology practice in the era of COVID-19 pandemic-related lockdowns - Experience from a tertiary hospital: A retrospective observational study. *Annals of Medicine and Surgery*, 68, 102641.
17. **Saleeb, R. M., Brimo, F., Gao, Y., Boulos, C., Kim, S. S., Al Bashir, S., Husain, A., Rotondo, F., Beharry, V., Bjarnason, G., Krizova, A., Trpkov, K., & Yousef, G. M. (2021).** ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade. *Human Pathology*, 114, 53-61.
18. **Ayoub, N. M., Fares, M., Marji, R., Al Bashir, S. M., & Yaghan, R. J. (2021).** Programmed Death-Ligand 1 Expression in Breast Cancer Patients: Clinicopathological Associations from a Single-Institution Study. *Breast Cancer: Targets and Therapy*, 13, 311-323.
19. **Kheirallah, K., Bloukh, S., Khasawneh, W., Alsulaiman, J., Khassawneh, A., Al-Mistarehi, A. H., Alqudah, M., Elsalem, L., Al Bashir, S., Awad, H. H., Al-Shatanawi, T., & Saleh, T. (2021).** Medical students' relative immunity, or lack thereof, against COVID-19 emotional distress and psychological challenges; a descriptive study from Jordan. *F1000Research*, 10, 194.
20. **Aldaoud, N., Graboski-Bauer, A., Abdo, N., Al Bashir, S., Oweis, A. O., Ebwaini, H., Hasen, Y., Alazab, R., & Trpkov, K. (2020).** ERG expression in prostate cancer biopsies with and without high-grade prostatic intraepithelial neoplasia: a study in Jordanian Arab patients. *Research and Reports in Urology*, 12, 193-200.
21. **Aldaoud, N., Hallak, A., Abdo, N., Al Bashir, S., Marji, N., & Graboski-Bauer, A. (2020).** Interobserver Variability in the Diagnosis of High-Grade Prostatic Intraepithelial Necrosis in a Tertiary Hospital in Northern Jordan. *Clinical Pathology*, 13, 2632010X20901458.
22. **Al Zoubi, M. S., Otoum, R., Alorjani, M. S., Al Bashir, S., Al Trad, B., Abualrja, M. I., Al-Khatib, S. M., & Al-Batayneh, K. (2020).** TP53, SPOP PIK3CA Genes Status in Prostate Cancer. *Asian Pacific Journal of Cancer Prevention*, 21(11), 3283-3289.
23. **Obeidat, R. A., Aleshawi, A. J., Obeidat, H. A., & Al Bashir, S. M. (2019).** A rare presentation of ovarian fibrothecoma in a middle age female: case report. *International Journal of Women's Health*, 11, 149-152.
24. **Alomari, S. O., Aleshawi, A. J., Marji, R., Dawaymeh, T., Al Bashir, S. M., & Alomari, A. H. (2019).** The largest malignant peripheral nerve sheath arising from the gluteal region: case report. *Journal of Surgical Case Reports*, 2019(3), rjz073.
25. **Al Bashir, S., Alzoubi, A., Alfaqih, M., Kheirallah, K., Smairat, A., Haddad, H., Al-Dwairy, A., Bani Fawwaz, B., Alzoubi, M., & Trpkov, K. (2018).** PTEN Loss in a Prostate Cancer Cohort from Jordan. *Applied Immunohistochemistry & Molecular Morphology*, 26(9), 675-680.
26. **Al-Husein, B. A., Dawah, B., Banihani, S. A., Al Bashir, S. M., Sawalmeh, K. M., & Ayoub, N. M. (2018).** Immunomodulatory effect of statins on regulatory T cells within human colorectal cancer is determined by the stage of disease. *Oncotarget*, 9(74), 33909-33923.
27. **Trpkov, K., Athanazio, D., Magi-Galluzzi, C., Yilmaz, H., Clouston, D., Agaimy, A., Williamson, S. R., Brimo, F., Lopez, J. I., Ulamec, M., Rioux-Leclercq, N., Kassem, M., Gupta, N., Hartmann, A., Leroy, X., Bashir, S. A., Yilmaz, A., & Hes, O. (2018).** Biphasic papillary renal cell carcinoma is a rare morphological variant with frequent multifocality: a

- study of 28 cases. *Histopathology*, 72(5), 777-785.
28. **Aldaoud, N., Abdo, N., Al Bashir, S., Alqudah, M., Marji, N., Alzoubi, H., & Alazab, R. (2017).** Prostate cancer in Jordanian-Arab population: ERG status and relationship with clinicopathologic characteristics. *Virchows Archiv*, 471(6), 753-759.
29. **Alazab, R. S., Ghawanmeh, H. M., Al-Okour, R. K., Alshammari, A., Lafi, T., Al-Karasneh, A. I., Al-Bashir, S., & Al-Ghazo, M. (2017).** Xanthogranulomatous Orchitis: Rare Case with Brief Literature Review. *Urology Case Reports*, 13, 92-93.
30. **Al-Muqbel, K. M., Yaghan, R. J., Al-Omari, M. H., Rousan, L. A., Dagher, N. M., & Al Bashir, S. (2016).** Clinical relevance of 18F-FDG-negative osteoblastic metastatic bone lesions noted on PET/CT in breast cancer patients. *Nuclear Medicine Communications*, 37(10), 1060-1067.
31. **Al Bashir, S., Alshalalfa, M., Hegazy, S. A., Dolph, M., Donnelly, B., & Bismar, T. T. (2014).** Cysteine-rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. *Journal of Hematology & Oncology*, 7(1), 21.
32. **Al Bashir, S., Yilmaz, A., Gotto, G., & Trpkov, K. (2014).** Long term outcome of primary urothelial papilloma: a single institution cohort. **Pathology**, 46(1), 37-40.
33. **Hansen, A., Alston, L., Tulk, S. E., Schenck, L. P., Grassie, M. E., Alhassan, B. F., Veermalla, A. T., Al-Bashir, S., Gendron, F. P., Altier, C., & Hirota, S. A. (2013).** The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. *PLoS One*, 8(11), e81491.
34. **Xu, B., Teng, L. H., Silva, S. D., Bijian, K., Al Bashir, S., Jie, S., Dolph, M., Alaoui-Jamali, M. A., & Bismar, T. A. (2013).** The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting. *Cancer Medicine*, 2(3), 289-301.
35. **Patel, P., Gotto, G., Kavanagh, A., Al Bashir, S., Bismar, T. A., & Trpkov, K. (2013).** Urinary bladder melanosis associated with urothelial dysplasia and invasive urothelial carcinoma: a report of two cases. *Analytical and Quantitative Cytology and Histology*, 35(5), 294-300.
36. **Hirota, S. A., Iablokov, V., Tulk, S. E., Schenck, L. P., Becker, H., Nguyen, J., Al Bashir, S., Dingle, T. C., Laing, A., Liu, J., et al. (2012).** Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. *Infection and Immunity*, 80(12), 4474-4484.
37. **Abu-Abeeleh, M., Matalka, I., Ismail, Z. A. B., Alzaben, K. R., Abu-Halaweh, S. A., Al Bashir, S., et al. (2010).** Efficacy of Human Adipose Tissue-Derived Stem cells in cardiac Muscle Repair In An Experimental Acute Myocardial Infarction Model Using Nude Mice. *Comparative Clinical Pathology*, 19(6), 593-600.
38. **Al-Hadithi, R. H., Alorjani, M. S., Al-Bashir, S., & Matalka, I. I. (2009).** Diaphragm disease of the jejunum. **Saudi Medical Journal**, 30(5), 702-704.
39. **Al-Qaoud, D., Al Manasra, A., Al Bashir, S., Fraiwan, N., & Saqan, R. (2010).** Successful outcome of early surgical debridement for pulmonary gangrene in a child. *The Internet Journal of Surgery*, 23(2).

RECENT CONFERENCE POSTER PRESENTATIONS

- **2023** — *PTEN and ERG status and relationship in a prostate cancer cohort from Jordanian Arab population*. 35th European Congress of Pathology (ECP 2023), Dublin, Ireland.
- **2022** — *Papillary Thyroid Microcarcinoma - Tall Cell variant arising in Mature Cystic Teratoma of the Ovary: Case Report*. 34th European Congress of Pathology (ECP 2022), Basel, Switzerland.
- **2019** — *PTEN, ERG, SPINK1 and TFE3 status and relationship in a prostate cancer cohort from an Arab population*. 31st European Congress of Pathology (ECP 2019), Nice, France.

This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes.